MNG1284
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.502
- ANGIOGENESIS+0.471
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.447
- CHOLESTEROL_HOMEOSTASIS+0.406
- ANDROGEN_RESPONSE+0.396
- APICAL_SURFACE+0.369
- PANCREAS_BETA_CELLS+0.343
- TGF_BETA_SIGNALING+0.341
- INFLAMMATORY_RESPONSE+0.339
- MYOGENESIS+0.325
Top 10 suppressed
- E2F_TARGETS-0.431
- DNA_REPAIR-0.386
- G2M_CHECKPOINT-0.354
- WNT_BETA_CATENIN_SIGNALING-0.301
- MYC_TARGETS_V2-0.299
- PI3K_AKT_MTOR_SIGNALING-0.271
- MYC_TARGETS_V1-0.239
- MITOTIC_SPINDLE-0.229
- OXIDATIVE_PHOSPHORYLATION-0.123
- SPERMATOGENESIS-0.094
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_6P50QTPP | low-grade glioma | — | 0.903 |
| 2 | 59627_S122 | — | cohortA4 | 0.897 |
| 3 | BS_5YJEPPTP | pilocytic astrocytoma | — | 0.884 |
| 4 | TCGA-AN-A03X-01A-21R-A00Z-07 | — | A | 0.882 |
| 5 | BS_5NWDARXG | pilocytic astrocytoma | — | 0.875 |
| 6 | BS_8VAZSJEN | pilocytic astrocytoma | — | 0.871 |
| 7 | 2eaa09cd-8e3e-4de9-ab96-7a290d780a01 | — | — | 0.868 |
| 8 | TCGA-38-4626-01A-01R-1206-07 | — | cohortMD2 | 0.867 |
| 9 | BS_52426AMF | low-grade glioma | — | 0.864 |
| 10 | SRR2932845 | — | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.502 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.471 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.447 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.406 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.396 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.369 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.343 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.341 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.339 | Idelalisib | — uncovered |
| MYOGENESIS | 0.325 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.319 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.307 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.305 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.305 | Remibrutinib | — uncovered |
| HYPOXIA | 0.287 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.264 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.228 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.223 | Inavolisib | — uncovered |